MX2019013642A - Compuestos, composiciones y metodos. - Google Patents
Compuestos, composiciones y metodos.Info
- Publication number
- MX2019013642A MX2019013642A MX2019013642A MX2019013642A MX2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A MX 2019013642 A MX2019013642 A MX 2019013642A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- compounds
- inflammation
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507682P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/033269 WO2018213634A1 (en) | 2017-05-17 | 2018-05-17 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019013642A true MX2019013642A (es) | 2020-07-20 |
Family
ID=64274734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013642A MX2019013642A (es) | 2017-05-17 | 2018-05-17 | Compuestos, composiciones y metodos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11174262B2 (enExample) |
| EP (1) | EP3625234B1 (enExample) |
| JP (2) | JP7140781B2 (enExample) |
| KR (1) | KR102637541B1 (enExample) |
| CN (1) | CN110914275A (enExample) |
| AU (2) | AU2018269745C1 (enExample) |
| BR (1) | BR112019023979A2 (enExample) |
| CA (1) | CA3063938A1 (enExample) |
| IL (1) | IL270505B2 (enExample) |
| MX (1) | MX2019013642A (enExample) |
| WO (1) | WO2018213634A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3552017B1 (en) * | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
| WO2018213634A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2022046905A1 (en) * | 2020-08-26 | 2022-03-03 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| WO2023076133A1 (en) * | 2021-10-27 | 2023-05-04 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
| WO2025045281A2 (zh) * | 2023-08-31 | 2025-03-06 | 杭州百诚医药科技股份有限公司 | 苯并氮杂䓬酮类化合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4320057A (en) * | 1980-06-23 | 1982-03-16 | American Home Products Corporation | Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones |
| US4290952A (en) * | 1980-06-23 | 1981-09-22 | American Home Products Corporation | Aryl-1-mercaptoalkanoylproline and homoproline derivatives |
| CN1960728A (zh) | 2004-01-16 | 2007-05-09 | 密歇根大学董事会 | 构象受限的smac模拟物及其应用 |
| EP2457895A1 (en) | 2004-07-12 | 2012-05-30 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
| BRPI0611922A2 (pt) | 2005-06-08 | 2010-10-05 | Novartis Ag | compostos orgánicos |
| TWI370130B (en) | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| AU2007276760B2 (en) | 2006-07-24 | 2012-01-19 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP antagonists |
| JP6465803B2 (ja) | 2012-10-22 | 2019-02-06 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | Ｅｔｐ誘導体 |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9944628B2 (en) * | 2014-12-11 | 2018-04-17 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
| JP6683712B2 (ja) * | 2014-12-24 | 2020-04-22 | ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン | ネクローシス阻害薬 |
| WO2018213634A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2018
- 2018-05-17 WO PCT/US2018/033269 patent/WO2018213634A1/en not_active Ceased
- 2018-05-17 CA CA3063938A patent/CA3063938A1/en active Pending
- 2018-05-17 CN CN201880047315.8A patent/CN110914275A/zh active Pending
- 2018-05-17 KR KR1020197036801A patent/KR102637541B1/ko active Active
- 2018-05-17 AU AU2018269745A patent/AU2018269745C1/en not_active Ceased
- 2018-05-17 EP EP18803112.4A patent/EP3625234B1/en active Active
- 2018-05-17 MX MX2019013642A patent/MX2019013642A/es unknown
- 2018-05-17 BR BR112019023979A patent/BR112019023979A2/pt active Search and Examination
- 2018-05-17 JP JP2019563609A patent/JP7140781B2/ja active Active
- 2018-05-17 IL IL270505A patent/IL270505B2/en unknown
-
2019
- 2019-11-14 US US16/683,970 patent/US11174262B2/en active Active
-
2021
- 2021-10-05 US US17/494,336 patent/US11851433B2/en active Active
-
2022
- 2022-04-14 AU AU2022202524A patent/AU2022202524B2/en not_active Ceased
- 2022-09-07 JP JP2022141824A patent/JP2022174180A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018213634A1 (en) | 2018-11-22 |
| CA3063938A1 (en) | 2018-11-22 |
| AU2018269745C1 (en) | 2022-06-09 |
| US11174262B2 (en) | 2021-11-16 |
| IL270505B2 (en) | 2023-09-01 |
| JP2020520925A (ja) | 2020-07-16 |
| IL270505A (enExample) | 2019-12-31 |
| CN110914275A (zh) | 2020-03-24 |
| IL270505B1 (en) | 2023-05-01 |
| AU2022202524A1 (en) | 2022-05-12 |
| EP3625234A4 (en) | 2021-03-10 |
| KR20200006120A (ko) | 2020-01-17 |
| US20200079784A1 (en) | 2020-03-12 |
| JP2022174180A (ja) | 2022-11-22 |
| AU2022202524B2 (en) | 2023-10-05 |
| AU2018269745A1 (en) | 2019-11-28 |
| JP7140781B2 (ja) | 2022-09-21 |
| EP3625234B1 (en) | 2023-09-20 |
| EP3625234A1 (en) | 2020-03-25 |
| KR102637541B1 (ko) | 2024-02-15 |
| AU2018269745B2 (en) | 2022-01-27 |
| US20220024938A1 (en) | 2022-01-27 |
| US11851433B2 (en) | 2023-12-26 |
| BR112019023979A2 (pt) | 2020-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| MX389228B (es) | Composiciones para tratar el cabello. | |
| MX378145B (es) | Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias | |
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
| PH12019550096A1 (en) | Beta-casein a2 and prevention of inflammation of the bowel | |
| AU2015287674B2 (en) | Topical antiviral compositions and methods of using the same | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| PH12017502255B1 (en) | Nrf2 regulators | |
| EA201691194A1 (ru) | Стимуляторы ргц | |
| NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| EP3804846A3 (en) | Design, synthesis and characterization of metal organic frameworks | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| MX2020010657A (es) | Derivados de oxadiazolina. | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX2019013642A (es) | Compuestos, composiciones y metodos. | |
| MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
| GB2568181A (en) | Wheat | |
| AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
| MX2017011521A (es) | Composiciones topicas que comprenden un corticosteroide. | |
| MX2017008390A (es) | Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato. | |
| MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
| SG10201900598TA (en) | Factor viii formulation | |
| EA202090732A1 (ru) | Составы для трансдермального введения |